20/20 Biolabs, Inc. (AIDX)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
AIDX Chart
20/20 Biolabs, Inc. (AIDX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has 20/20 Biolabs, Inc. ever had a stock split?
20/20 Biolabs, Inc. Profile
| Health Care Equipment & Supplies Industry | Healthcare Sector | Jonathan Cohen CEO | NASDAQ (NMS) Exchange | 90138K101 CUSIP |
| US Country | 13 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
20/20 GeneSystems, Inc. is a clinical laboratory testing company that specializes in cancer screening and viral testing services. Founded in 2000 and headquartered in Gaithersburg, Maryland, the company is dedicated to advancing early cancer detection through innovative blood testing solutions. It offers a multi-cancer early detection blood test system, prominently featuring the OneTest, which aids in identifying various cancers at an early stage. Additionally, the company has expanded its focus to include viral testing, providing rapid COVID-19 test kits to meet the urgent needs of healthcare providers and patients alike.
20/20 GeneSystems operates the Clinical Lab Innovation Axcelerator (CLIAx), a collaborative laboratory facility designed to support diagnostic test developers in navigating the complexities of bringing their products to market in the U.S. By enabling access to shared laboratory space and resources, the company also nurtures the growth of diagnostic startups. Moreover, 20/20 GeneSystems delivers its advanced cancer screening algorithm technology via a Software as a Service (SaaS) platform, partnering with healthcare providers to enhance patient care and improve diagnostic outcomes.
Products and Services
- OneTest
A multi-cancer early detection blood test that identifies indicators of various cancers, allowing for timely diagnosis and intervention. The test leverages advanced algorithms to enhance precision in screening, thereby improving patient outcomes.
- Rapid COVID-19 Test Kits
Includes the Assure COVID-19 IgG/IgM rapid test that provides quick results for COVID-19 screening. These kits are crucial for healthcare settings seeking immediate testing solutions, enabling better management of patient care and public health safety.
- Clinical Lab Innovation Axcelerator (CLIAx)
A shared laboratory facility that facilitates the development and commercialization of diagnostic tests. This initiative supports startups and established companies alike by providing access to necessary laboratory resources, regulatory guidance, and collaborative opportunities.
- Cancer Screening Algorithm Technology
Delivered through a Software as a Service (SaaS) platform, this technology allows healthcare providers to integrate advanced cancer screening methodologies into their practices. The platform enhances the diagnostic process, ensuring better detection rates and patient care.
